The size of the metastatic lymph nodes under my left clavicle have continued to slowly boost in size. They have now passed the threshold of 1.5 cm inside the fast axis, which signifies that I now am eligible to take part in NIH's clinical trials. More on that later.
The scans showed that there have been a host of a little bit enlarged nodes in my abdomen. Those nodes aren't pathologically significant, which signifies that they are under 1.0 cm in size. Those nodes have been also widespread inside the last couple of scans. We don't now if they are turning out to be because of metastatic online game or a host of other reason, since they failed to categorical up as "hot" in my last PET scan in September 2014. But it is pretty more likely than now not that the boom is associated to metastatic online game.
There became no evidence of tumors in my liver, lungs, bones, or any other organs.
The CT urogram showed no evidence of kidney cancer.
The pulmonary embolisms and clots in my important hepatic portal have been thoroughly resolved.
There is nothing unusual from these outcomes. I've familiar since September that my superclavicular nodes have metastatic online game. Each scan since then has shown a slow boost in size, of roughly 1 mm per month. In November 2014, the node became measured to be 1.forty two cm on the fast axis. Now it is pretty over 1.5 cm. No wonder there. The unparalleled news is the absence of tumors in assorted places, at the side of ruling out that the refreshing blood in my urine became due to the kidney cancer.
Dr. Apolo pointed out that, now that my nodes have been of ok size to go into clinical trials, we may though talk about whether I may though enter a trial, and if so, which one. NIH is currently running five clinical trials for patients with stage 4 bladder cancer. One is a Phase I trial of an AdHER2 vaccination. This is the clinical trial that I became being evaluated for in October when my PE became found. Another is a Phase II study of cabozantinib, a new chemical entity that inhibits multiple receptor tyrosine kinases with boom-promoting and angiogenic properties. The functional goals of cabozantinib are MET, VEGFR2, and RET. Dr. Apolo is the principal investigator of this trial, so I think she has a bias toward having me participate in it.
In addition, there are also clinical trials exterior of NIH that I could talk about. The highest compelling option is a Hoffman-Laroche sponsored study of MPDL3280a. I've previously blogged roughly this drug; initial outcomes have shown nice promise, supporting slow or cease tumor boom in 50% of patients. The drug became designated a "breakthrough treatment" by the FDA last summer. I'll be meeting with Dr. Apolo on Tuesday after my cytoscopy, and may be questioning her in detail roughly my clinical trial percentages.